Replies to post #2213 on InVivo Therapeutics Holdings Corp (NVIVQ)

[pistol1p]

Frank Reynolds, the former CEO, pumped the company and the stock above the $5.50 mark last year.

He had been quoting a timeline for clinical trials and uplisting, which he was unable to deliver on. NVIV stock subsequently dropped below $1.50 pps and new management has the first clinical trial site almost ready to deploy the scaffolding into the first patient.

Good luck to all the longs.